Eton Launches U.S. Commercial Availability of IMPAVIDO
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...
GHENT, Belgium and TOKYO, Japan, September 1, 2026 Fujirebio, a wholly owned subsidiary of H.U. Group Holdings, announced that...
SALT LAKE CITY, Utah, August 10, 2026 Clene Inc. announced new biomarker analyses for CNM-Au8 that will be included...
